Online citations, reference lists, and bibliographies.
← Back to Search

Multicystic Peritoneal Mesothelioma: Outcomes And Patho-biological Features In A Multi-institutional Series Treated By Cytoreductive Surgery And Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

D. Baratti, M. Vaira, S. Kusamura, S. D'amico, M. R. Balestra, T. Cioppa, E. Mingrone, M. De Simone, M. Deraco
Published 2010 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
AIM This retrospective multi-institutional study addresses the role of surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of multicystic peritoneal mesothelioma (MCPM). MCPM is an uncommon tumour with uncertain malignant potential and no current standard therapy. Additionally, poorly defined pathological and biological features of this disease were investigated. METHODS Twelve patients with MCPM underwent 14 procedures of cytoreduction and HIPEC in two Italian referral centres. Nine patients had recurrent disease after previous debulking (one operation in six patients, two in two, four in one). Biological markers related to mesothelioma origin and clinical features were assessed by immunohistochemical studies. RESULTS Median follow-up was 64 months (range 5-148). Optimal cytoreduction (residual tumour nodules ≤2.5 mm) was performed in all the procedures. One grade IV postoperative complication (NCI/CTCAE v.3.0) and no operative death occurred. All the patients are presently alive with no evidence of disease, including two patients who underwent the procedure twice, due to locoregional disease recurrence. Five- and ten-year progression-free survival was 90% and 72%, accounting for a. statistically significant difference (P = 0.0001) with progression-free survival following previous debulking surgery (median 11 months; range 2-31). All cases showed low proliferative activity assessed by mitotic rate and Ki-67 expression. CONCLUSIONS MCPM is a borderline tumour with a high propensity to local-regional recurrence. Definitive tumour eradication by means of cytoreduction and HIPEC seems more effective than debulking surgery in preventing disease relapse. Low mitotic rate and poor Ki-67 expression might be related to the peculiar behaviour of MCMP.
This paper references
10.1177/030089160809400104
Thin-Walled Cysts as a Pathognomonic CT Finding in Cystic Mesothelioma
P. Sugarbaker (2008)
10.1097/00000421-198212000-00014
Toxicity and response criteria of the Eastern Cooperative Oncology Group
M. Oken (1982)
Benign cystic mesothelioma of the peritoneum.
S. Kyzer (1994)
10.1177/030089160308900107
Peritoneal Cystic Mesothelioma: A Case Series
K. Sethna (2003)
[Peritoneal mesothelioma: treatment with cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy].
G. Passot (2008)
10.1002/JSO.10190
Semi‐closed hyperthermic‐antiblastic peritoneal perfusion (HAPP) in the treatment of peritoneal carcinosis
M. De Simone (2003)
10.1245/s10434-009-0756-2
Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma
D. Baratti (2009)
10.1016/S0021-7697(08)74654-4
Mésothéliome péritonéal : traitement par l’association chirurgie de cytoréduction et chimiothérapie hyperthermique intrapéritonéale
G. Passot (2008)
10.1043/1543-2165(2006)130[1654:PSOHPI]2.0.CO;2
Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma.
C. Cerruto (2006)
[Treatment of peritoneal mesothelioma using cytoreduction and intraperitoneal hyperthermic chemotherapy].
D. Costamagna (2003)
10.1097/PGP.0b013e3181aae8f6
Lymph node involvement in multicystic peritoneal mesothelioma.
Corinne Engohan-Aloghe (2009)
10.1007/s12253-009-9170-0
Differential Expression of Ki-67 and Sex Steroid Hormone Receptors Between Genders in Peritoneal Mesothelioma
Terence C. Chua (2009)
10.1002/JSO.10081
Malignant transformation of “benign” cystic mesothelioma of the peritoneum
S. González-Moreno (2002)
10.1016/j.ejso.2008.09.010
Cytoreductive surgery and intraperitoneal chemotherapy for peritoneal mesothelioma.
H. Yano (2009)
10.1043/1543-2165-133.8.1317
Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group.
A. Husain (2009)
10.1200/JCO.2003.04.150
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
A. Feldman (2003)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
Trattamento del mesotelioma peritoneale mediante citoriduzione e chemioipertermia intraperitoneale (CIIP)
D Costamagna (2003)
10.1053/HUPA.2003.31
Benign cystic mesothelioma of the peritoneum: a clinicopathologic study of 17 cases and immunohistochemical analysis of estrogen and progesterone receptor status.
R. Sawh (2003)
Multicystic peritoneal mesothelioma treated by surgical cytoreduction and hyperthermic intra-peritoneal chemotherapy (HIPEC).
D. Baratti (2008)
10.1016/s1055-3207(03)00048-6
Peritonectomy procedures.
P. Sugarbaker (1996)
10.1007/978-1-4612-4380-9_25
Nonparametric Estimation from Incomplete Observations
E. L. Kaplan (1958)
10.1097/SLA.0b013e3181a45d86
Should the Treatment of Peritoneal Carcinomatosis by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Still be Regarded as a Highly Morbid Procedure?: A Systematic Review of Morbidity and Mortality
T. Chua (2009)
10.1002/cncr.10176
Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis
Carlo R. Rossi (2002)
Multicystic peritoneal mesothelioma. A case report.
N. Blumberg (1981)
10.1097/00000478-198810000-00001
Multicystic Mesothelioma: An Analysis of Pathologic Findings and Biologic Behavior in 37 Cases
S. Weiss (1988)
10.1155/2007/456839
Survivin is Highly Expressed and Promotes Cell Survival in Malignant Peritoneal Mesothelioma
N. Zaffaroni (2007)
10.1245/s10434-006-9169-7
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
T. Yan (2006)
10.1002/1097-0142(19890915)64:6<1336::AID-CNCR2820640628>3.0.CO;2-X
Multilocular peritoneal inclusion cysts (So‐called cystic mesotheliomas)
M. J. Ross (1989)
Current methodologies for clinical assessment of patients with peritoneal carcinomatosis
P Jaquet (1996)
10.1097/OGX.0b013e31819f93d4
Peritoneal Inclusion Cysts: A Review
A. Vallerie (2009)
10.1245/s10434-007-9475-8
Multicystic and Well-differentiated Papillary Peritoneal Mesothelioma Treated by Surgical Cytoreduction and Hyperthermic Intra-peritoneal Chemotherapy (HIPEC)
D. Baratti (2007)
10.1002/1097-0142(19821015)50:8<1615::AID-CNCR2820500826>3.0.CO;2-K
Cystic mesothelioma of the peritoneum. A report of five cases and review of the literature
Y. Katsube (1982)



This paper is referenced by
10.1097/PAT.0000000000000181
Diffuse mesothelioma of the peritoneum: correlation between histological and clinical parameters and survival in 73 patients
S. Liu (2014)
10.3978/j.issn.2078-6891.2015.112
Cytoreductive surgery and intraperitoneal chemotherapy: an evidence-based review-past, present and future.
Ahmed Dehal (2016)
10.1200/EdBook_AM.2013.33.182
Peritoneal mesothelioma: the site of origin matters.
H. Kindler (2013)
10.1515/pp-2019-0024
Multicystic peritoneal mesothelioma: a systematic review of the literature
B. Noiret (2019)
10.1155/2017/9752908
Benign Multicystic Peritoneal Mesothelioma: A Rare Condition in an Uncommon Gender
M. Khurram (2017)
10.1155/2018/4324986
Benign Multicystic Peritoneal Mesothelioma in a Male Patient with Previous Wilms' Tumor: A Case Report and Review of the Literature
G. L. Canu (2018)
10.5833/JJGS.2012.0222
A Case of Benign Multicystic Peritoneal Mesothelioma Combined with Adenomatoid Tumor of the Omentum
Shunichi Ishigami (2013)
10.1155/2019/6351874
Analysis of Bacterial and Fungal Infections after Cytoreduction Surgery and Hyperthermic Intraperitoneal Chemotherapy: An Observational Single-Centre Study
T. M. Al-Bukhari (2019)
10.1093/jscr/rjz057
Benign Multicystic Peritoneal Mesothelioma (BMPM) as a rare cause of abdominal pain in a young male: case report and review of the literature
S. Gussago (2019)
10.3748/wjg.v20.i33.11700
Advances in the management of peritoneal mesothelioma.
A. Raza (2014)
10.1016/j.ejso.2018.03.004
Multicystic mesothelioma: Operative and long-term outcomes with cytoreductive surgery and hyperthermic intra peritoneal chemotherapy.
E. Nizri (2018)
10.1016/j.currproblcancer.2017.03.002
Multicystic peritoneal mesothelioma: A short review.
Chihao Zhang (2017)
10.1186/s13256-016-0826-6
Benign multicystic mesothelioma of peritoneum complicating acute appendicitis in a man: a case report
S. Occhionorelli (2016)
10.1186/s13023-017-0571-y
The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
L. Villeneuve (2017)
10.4081/JOPER.2017.52
Multicystic mesothelioma has malignant potential: its grounds and mechanisms of peritoneal metastasis
Y. Yonemura (2017)
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC) – Community Plan Medical Policy
(2020)
10.1016/j.ejso.2020.02.011
Peritoneal mesothelioma: PSOGI/EURACAN clinical practice guidelines for diagnosis, treatment and follow-up.
S. Kusamura (2020)
10.1097/PAT.0b013e3283631cce
Diffuse mesothelioma of the peritoneum: a pathological study of 64 tumours treated with cytoreductive therapy
M. Lee (2013)
10.1055/S-0043-100104
Das benigne multizystische peritoneale Mesotheliom (BMPM) – Eine überraschende Differenzialdiagnose bei Verdacht auf einen intraabdominellen Abszess
Michael J. Lipp (2017)
10.21037/jgo.2017.08.01
Clinical presentation, diagnosis, classification and management of peritoneal mesothelioma: a review.
A. García-Fadrique (2017)
10.1245/s10434-014-3978-x
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma: A Systematic Review and Meta-analysis
J. H. Helm (2014)
10.4155/tde.11.112
Development of regional chemotherapies: feasibility, safety and efficacy in clinical use and preclinical studies.
S. Cai (2011)
10.1002/pbc.28286
Multicystic and diffuse malignant peritoneal mesothelioma in children
Sophie Vermersch (2020)
10.1016/j.suronc.2014.12.002
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with oxaliplatin for peritoneal mesothelioma: preliminary results and survival analysis.
J. Hubert (2015)
10.1002/jso.23449
Peritoneal debulking/intraperitoneal chemotherapy—non‐sarcoma
K. Kelly (2014)
10.1245/s10434-018-6499-1
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival
V. Verma (2018)
10.1016/J.GMIT.2014.12.001
Multicystic peritoneal mesothelioma after fertility-sparing surgery for an ovarian tumor of borderline malignancy: A case report
H. Nomura (2015)
10.1016/j.ijscr.2020.07.074
Multicystic peritoneal mesothelioma treated with complete cytoreductive surgery, peritonectomy and hyperthermic intra-peritoneal chemotherapy—A case report
Naveen Padmanabhan (2020)
Impact d’un réseau national sur la prise en charge des tumeurs rares du péritoine
L. Villeneuve (2017)
Intraoperative Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
UnitedHealthcare SignatureValue (2013)
10.1055/s-0043-100104
[Benign multicystic peritoneal mesothelioma (BMPM) - a surprising differential diagnosis in case of an expected intraabdominal abscess formation].
M. Lipp (2017)
10.1016/j.canlet.2014.12.002
Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13).
I. Panagopoulos (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar